Senzime Ab Stock Price, News & Analysis
Company Description
Senzime AB (SNZZF) develops and markets medical device systems for precision monitoring in anesthesia and perioperative care. The company’s flagship TetraGraph system monitors neuromuscular transmission during surgery, a clinical function used to guide dosing of neuromuscular blocking drugs and support recovery from anesthesia. Senzime is headquartered in Uppsala, Sweden, was established in 1999, is listed on the Nasdaq Stockholm Main Market under SEZI, and its ordinary shares cross-trade on the OTCQX Market as SNZZF.
The company’s product focus is centered on perioperative patient safety and operating-room monitoring. TetraGraph is used by anesthesia teams to generate objective neuromuscular data during surgical care. The system is marketed to hospitals and health systems, including integrated delivery networks in the United States, where centralized purchasing decisions can support system-wide adoption across affiliated facilities.
Senzime also offers TetraCom, a hospital connectivity platform designed to transmit real-time neuromuscular data from TetraGraph into electronic health record and clinical information systems. TetraCom combines a compact hardware gateway with a cloud-based software component and uses HL7 messaging to support interoperability with hospital enterprise systems such as Epic and Oracle Health systems. This extends the company’s role from device-based monitoring into anesthesia data integration for hospital information environments.
The company’s commercial model includes sales of monitoring systems to hospitals and healthcare networks, along with recurring revenue associated with installed systems. In the United States, Senzime’s commercial activity includes hospital contracts, integrated delivery network expansion, and access through group purchasing organization agreements. Its operating structure also includes sales, clinical, and medical-affairs functions that support hospital adoption, training, and use of the company’s monitoring technology.
Senzime operates within the medical device market for perioperative and anesthesia care. Its business is shaped by hospital procurement processes, operating-room clinical practice, and the broader shift toward quantitative monitoring and digital transmission of clinical data during surgery and recovery.
Stock Performance
Senzime Ab (SNZZF) stock last traded at $0.4785. Over the past 12 months, the stock has lost 7.1%. At a market capitalization of $94.2M, SNZZF is classified as a micro-cap stock with approximately 157.2M shares outstanding.
Latest News
Senzime Ab has 10 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 1 with negative movement. View all SNZZF news →
SEC Filings
Financial Highlights
Upcoming Events
U.S. product introduction
Senzime Ab has 1 upcoming scheduled event. The next event, "U.S. product introduction", is scheduled for July 1, 2026 (in 17 days). Investors can track these dates to stay informed about potential catalysts that may affect the SNZZF stock price.
Short Interest History
Short interest in Senzime Ab (SNZZF) currently stands at 2.0 thousand shares, down 88.8% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 70.3%. This relatively low short interest suggests limited bearish sentiment. With 1000.0 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Senzime Ab (SNZZF) currently stands at 1000.0 days. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 9889.9% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
SNZZF Company Profile & Sector Positioning
Senzime Ab (SNZZF) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing SNZZF often look at related companies in the same sector, including QT Imaging Holdings (QTIH), RETINALGENIX TECHNOLOGIES INC (RTGN), Cannabix Technol (BLOZF), Positron (POSC), and Acarix AB (ACIXF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SNZZF's relative position within its industry.